All In Biotech

Drug Trial Radar · NCT07136974

Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.

Comparing the Efficacy of TQB2102 and TCbHP in Neoadjuvant Treatment for HER2-positive Early Breast Cancer: A Randomized Phase II Clinical Trial.

Last checked: Nov 19, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 280 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

280

Planned (sponsor's estimate)

Start

Sep 1, 2025

Primary completion

Aug 30, 2028

Study completion Aug 30, 2030

Sponsor

Lead sponsor
Henan Cancer HospitalGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Aug 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to evaluate the efficacy and safety of TQB2102 compared to TCbHP in the neoadjuvant treatment of HER2-positive breast cancer. Participants will randomly assigned, in a 1:1 ratio, to receive either TQB2102 or TCbHP for 6 cycles. Patients will undergo definitive surgery (breast conservation or mastectomy with sentinel lymph-node evaluation or axillary dissection) 3 to 6 weeks after the last cycle of the neoadjuvant phase. Primary endpoint is pathological complete response, defined as pathological stage ypT0/Tis ypN0 at the time of definitive surgery.

Conditions

  • Breast Cancer
  • HER2 + Breast Cancer

Interventions

  • TQB2102Drug

    TQB2102 is administered intravenously at 6 mg/kg every 3 weeks for 6 cycles.

  • Docetaxel + Carboplatin + Trastuzumab +PertuzumabDrug

    Docetaxel 75 mg/m2(day 1) , Carboplatin (AUC=6) (day 1), Trastuzumab (8mg/kg first dose, 6mg/kg sequential) and Pertuzumab (840mg first dose, 420mg/kg sequential) are administered intravenously every 3 weeks for 6 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathological Complete Response (pCR)Time frame: up to 180 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Henan cancer hospital

    Zhengzhou, Henan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.